AHA/ACC guidance formalizes hypertension management in pregnancy and emphasizes cardiovascular risk stratification using the ...

Advanced cardiovascular-kidney-metabolic (CKM) syndrome stage, especially stages 3 and 4, is associated with increased cancer risk.

The Centers for Medicare & Medicaid Services (CMS) has announced that its temporary program to cover GLP-1 drugs for obesity in Medicare.

Chronic oral glucocorticoid use is linked to increased mortality, with risk rising alongside higher cumulative exposure and daily doses.

HealthDay News — For patients with chronic kidney disease (CKD), cognitive impairment (CI) is associated with worse outcomes, according to a study published in the May issue of Kidney International ...

The American Academy of Physician Associates and the PA Education Association plan to challenge the ruling in federal court.

A new guideline for acute pulmonary embolism developed by 10 major specialty societies introduces a novel PE clinical ...

Survodutide, a dual GLP-1 and glucagon receptor agonist, significantly reduced body weight in adults with obesity in the SYNCHRONIZE-1 trial.

Treatment with a once-daily pill containing 3 low-dose antihypertensive agents is associated with a lower incidence of recurrent stroke.

Coramitug is currently being investigated in the phase 3 CLEOPATTRA trial in approximately 1280 patients with ATTR-CM.

A new proposal could make it easier for many patients to access breakthrough medical devices through Medicare.

Machine learning models can predict the risk for developing moderate-to-severe persistent asthma and allergic rhinitis in children with early-life AD.